BioSpace News Archive

The acquisition of Nuevolution and its Chemetics platform will expand Amgen’s ability to discover novel small molecules against difficult-to-drug targets.

The deal will grow Evotec’s business into a comprehensive offering including biologics in therapeutic areas such as oncology, CNS, pain, inflammation, metabolics and infectious diseases.

AlloVir is working to develop an allogeneic cell therapy to control infections in immunocompromised patients, typically after they undergo organ transplants.

Synlogic is partnering with Roche to develop Synlogic’s SYNB1891 with Roche’s checkpoint inhibitor Tecentriq (atezolizumab) in advanced solid tumors.

Biopharma companies from across Europe share pipeline and strategy updates.

FDA Chief of Staff Lauren Silvis indicated the FDA is “pushing forward” with its nonprescription safe use regulatory expansion (NSURE) program, and that “OTC monograph reform remains a top priority for the agency” but “it’s up to Congress to legislate the issue.”

The Integrated Mitotic Stem Cell merges images of 15 separate cellular components, creating a 3-dimensional map of what a human cell looks like during different steps in cell division. The idea is that it can assist researchers in better understanding how the separate stages and different components of the cell work together.

Sorilux was approved for the treatment of patients age 12 and up.

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery (“MIS”), announces that its 2019 Annual and Special Meeting is scheduled for Wednesday, May 29, 2019 at 12:00 p.m.

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces its unaudited interim results for the six months ended 31 March 2019.